{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:29:28Z","timestamp":1789687768764,"version":"4.0.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microbial Pathogenesis"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.micpath.2018.05.035","type":"journal-article","created":{"date-parts":[[2018,5,23]],"date-time":"2018-05-23T16:45:04Z","timestamp":1527093904000},"page":"218-223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"special_numbering":"C","title":["Are chitosan natural polymers suitable as adjuvant\/delivery system for anti-tuberculosis vaccines?"],"prefix":"10.1016","volume":"121","author":[{"given":"Farzad","family":"Khademi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1394-6412","authenticated-orcid":false,"given":"Ramazan-Ali","family":"Taheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshid","family":"Yousefi Avarvand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Vaez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4376-1083","authenticated-orcid":false,"given":"Amir Abbas","family":"Momtazi-Borojeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saman","family":"Soleimanpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.micpath.2018.05.035_bib1","first-page":"15","article-title":"Mycobacterium tuberculosis HspX\/EsxS fusion protein: gene cloning, protein expression, and purification in Escherichia coli","volume":"6","author":"Khademi","year":"2017","journal-title":"Reports of Biochem. Mol. Biol."},{"key":"10.1016\/j.micpath.2018.05.035_bib2","first-page":"133","article-title":"The role of toll-like receptor gene polymorphisms in tuberculosis susceptibility: a systematic review and meta-analysis","volume":"3","author":"Khademi","year":"2016","journal-title":"Rev. Clin. Med."},{"key":"10.1016\/j.micpath.2018.05.035_bib3","doi-asserted-by":"crossref","first-page":"10467","DOI":"10.1007\/s00253-015-6952-z","article-title":"APC targeting enhances immunogenicity of a novel multistage Fc-fusion tuberculosis vaccine in mice","volume":"99","author":"Soleimanpour","year":"2015","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.micpath.2018.05.035_bib4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1146\/annurev-publhealth-031912-114431","article-title":"Prospects for tuberculosis elimination","volume":"34","author":"Dye","year":"2013","journal-title":"Annu. Rev. Publ. Health"},{"key":"10.1016\/j.micpath.2018.05.035_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/14760584.2018.1406309","article-title":"Multi-stage subunit vaccines against Mycobacterium tuberculosis: an alternative to the BCG vaccine or a BCG-prime boost?","volume":"17","author":"Khademi","year":"2018","journal-title":"Expet Rev. Vaccine"},{"key":"10.1016\/j.micpath.2018.05.035_bib6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fcimb.2013.00013","article-title":"Vaccine delivery using nanoparticles","volume":"3","author":"Gregory","year":"2013","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.micpath.2018.05.035_bib7","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1021\/acs.bioconjchem.6b00116","article-title":"Potent antigen-adjuvant delivery system by conjugation of Mycobacterium tuberculosis Ag85B-HspX fusion protein with arabinogalactan-poly(I: C) conjugate","volume":"27","author":"Huang","year":"2016","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.micpath.2018.05.035_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.tim.2006.11.008","article-title":"Vaccine strategies against latent tuberculosis infection","volume":"15","author":"Andersen","year":"2007","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.micpath.2018.05.035_bib9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.smim.2013.04.006","article-title":"Tuberculosis vaccines: time to think about the next generation","volume":"25","author":"Kaufmann","year":"2013","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.micpath.2018.05.035_bib10","first-page":"227","article-title":"Development of novel Carrier(s) mediated tuberculosis vaccine: more than a tour de force","volume":"62","author":"Garg","year":"2014","journal-title":"Eur. J. Pharmaceut. Sci. Offic. J Eur. Fed. Pharm. Sci."},{"key":"10.1016\/j.micpath.2018.05.035_bib11","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s13238-015-0164-2","article-title":"Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies","volume":"6","author":"Wang","year":"2015","journal-title":"Protein & cell"},{"key":"10.1016\/j.micpath.2018.05.035_bib12","doi-asserted-by":"crossref","first-page":"e1002607","DOI":"10.1371\/journal.ppat.1002607","article-title":"Vaccines against tuberculosis: where are we and where do we need to go?","volume":"8","author":"Ottenhoff","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.micpath.2018.05.035_bib13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ajps.2014.06.002","article-title":"Nanotechnology and vaccine development","volume":"9","author":"Mi-Gyeong Kim","year":"2014","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.micpath.2018.05.035_bib14","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jconrel.2011.12.039","article-title":"Towards tailored vaccine delivery: needs, challenges and perspectives","volume":"161","author":"Amorij","year":"2012","journal-title":"J. Contr. Release. Offic. J. Contr. Release Soci."},{"key":"10.1016\/j.micpath.2018.05.035_bib15","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: an overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J. Contr. Release. Offic. J. Contr. Release Soci."},{"key":"10.1016\/j.micpath.2018.05.035_bib16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jconrel.2004.10.010","article-title":"Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions","volume":"102","author":"Yamamoto","year":"2005","journal-title":"J. Contr. Release. Offic. J. Contr. Release Soci."},{"key":"10.1016\/j.micpath.2018.05.035_bib17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejpb.2003.09.006","article-title":"Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice","volume":"57","author":"Vila","year":"2004","journal-title":"Eur. J. Pharm. Biopharm. Offic. J. Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV"},{"key":"10.1016\/j.micpath.2018.05.035_bib18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.addr.2009.11.009","article-title":"Chitosan-based delivery systems for protein therapeutics and antigens","volume":"62","author":"Amidi","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.micpath.2018.05.035_bib19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.nano.2012.06.001","article-title":"Polymeric nanogels as vaccine delivery systems","volume":"9","author":"Ferreira","year":"2013","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.micpath.2018.05.035_bib20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0168-3659(00)00361-8","article-title":"Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency","volume":"70","author":"Mao","year":"2001","journal-title":"J. Contr. Release. Offic. J. Contr. Release Soci."},{"key":"10.1016\/j.micpath.2018.05.035_bib21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ijpharm.2008.06.029","article-title":"Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery","volume":"363","author":"Sayin","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.micpath.2018.05.035_bib22","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.4049\/jimmunol.1200492","article-title":"Tuning innate immune activation by surface texturing of polymer microparticles: the role of shape in inflammasome activation","volume":"190","author":"Vaine","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.micpath.2018.05.035_bib23","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/icb.2014.21","article-title":"Activation of the NLRP3 inflammasome is not a feature of all particulate vaccine adjuvants","volume":"92","author":"Neumann","year":"2014","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.micpath.2018.05.035_bib24","first-page":"51","article-title":"Chitosan nanoparticles : a promising system for drug delivery","volume":"11","author":"Tiyaboonchai","year":"2003","journal-title":"Naresuan Univ. J."},{"key":"10.1016\/j.micpath.2018.05.035_bib25","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1166\/jbn.2014.1984","article-title":"Approaches to tuberculosis mucosal vaccine development using nanoparticles and microparticles: a review","volume":"10","author":"Caetano","year":"2014","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.micpath.2018.05.035_bib26","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1124\/dmd.114.059238","article-title":"Subcutaneous absorption of biotherapeutics: knowns and unknowns","volume":"42","author":"Richter","year":"2014","journal-title":"Drug Metab. Dispos.: the biological fate of chemicals"},{"key":"10.1016\/j.micpath.2018.05.035_bib27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0378-5173(01)00602-0","article-title":"Clearance characteristics of chitosan based formulations in the sheep nasal cavity","volume":"217","author":"Soane","year":"2001","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.micpath.2018.05.035_bib28","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/1348-0421.12027","article-title":"Enhanced protection against pulmonary mycobacterial challenge by chitosan-formulated polyepitope gene vaccine is associated with increased pulmonary secretory IgA and gamma-interferon(+) T cell responses","volume":"57","author":"Ai","year":"2013","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.micpath.2018.05.035_bib29","doi-asserted-by":"crossref","first-page":"e61135","DOI":"10.1371\/journal.pone.0061135","article-title":"Enhanced immune response and protective effects of nano-chitosan-based DNA vaccine encoding T cell epitopes of Esat-6 and FL against Mycobacterium tuberculosis infection","volume":"8","author":"Feng","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.micpath.2018.05.035_bib30","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.2147\/IJN.S36111","article-title":"The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles","volume":"7","author":"Frohlich","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.micpath.2018.05.035_bib31","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1189\/jlb.4A0616-270R","article-title":"Rationalized design of a mucosal vaccine protects against Mycobacterium tuberculosis challenge in mice","volume":"101","author":"Ahmed","year":"2017","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.micpath.2018.05.035_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biomaterials.2016.09.027","article-title":"Layer-by-layer nanocoating of live Bacille-Calmette-Gu\u00e9rin mycobacteria with poly (I: C) and chitosan enhances pro-inflammatory activation and bactericidal capacity in murine macrophages","volume":"111","author":"Speth","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.micpath.2018.05.035_bib33","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1021\/acs.molpharmaceut.6b00138","article-title":"Conjugation with an inulin-chitosan adjuvant markedly improves the immunogenicity of Mycobacterium tuberculosis CFP10-TB10.4 fusion protein","volume":"13","author":"Yu","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.micpath.2018.05.035_bib34","first-page":"223","article-title":"Chitosan (CHT) and trimethylchitosan (TMC) nanoparticles as adjuvant\/delivery system for parenteral and nasal immunization against Mycobacterium tuberculosis (MTb) ESAT-6 antigen","volume":"3","author":"Karimi","year":"2016","journal-title":"Nanomed. J."},{"key":"10.1016\/j.micpath.2018.05.035_bib35","first-page":"4","article-title":"Ag85A DNA vaccine delivery by nanoparticles: influence of the formulation characteristics on immune responses","author":"Poecheim","year":"2016","journal-title":"Vaccines"},{"key":"10.1016\/j.micpath.2018.05.035_bib36","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.vaccine.2012.11.075","article-title":"Enhancement of immune response to a DNA vaccine against Mycobacterium tuberculosis Ag85B by incorporation of an autophagy inducing system","volume":"31","author":"Meerak","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2018.05.035_bib37","series-title":"Bioengineering 2012;IEEE 2nd Portuguese Meeting in","article-title":"Alginate-chitosan particulate delivery systems for mucosal immunization against tuberculosis","author":"Caetano","year":"2012"},{"key":"10.1016\/j.micpath.2018.05.035_bib38","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ejpb.2006.11.028","article-title":"Chitosan microspheres enhance the immunogenicity of an Ag85B-based fusion protein containing multiple T-cell epitopes of Mycobacterium tuberculosis","volume":"66","author":"Zhu","year":"2007","journal-title":"Eur. J. Pharm. Biopharm. Offic. J. Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV"},{"key":"10.1016\/j.micpath.2018.05.035_bib39","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.vaccine.2003.09.044","article-title":"Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis","volume":"22","author":"Bivas-Benita","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2018.05.035_bib40","doi-asserted-by":"crossref","first-page":"165101","DOI":"10.1088\/1361-6528\/aa60fd","article-title":"Biocompatible chitosan nanoparticles as an efficient delivery vehicle for Mycobacterium tuberculosis lipids to induce potent cytokines and antibody response through activation of gammadelta T cells in mice","volume":"28","author":"Das","year":"2017","journal-title":"Nanotechnology"},{"key":"10.1016\/j.micpath.2018.05.035_bib41","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3109\/21691401.2016.1146735","article-title":"Development of an effective delivery system for intranasal immunization against Mycobacterium tuberculosis ESAT-6 antigen","volume":"45","author":"Amini","year":"2017","journal-title":"Artif. Cell. Nanomed. Biotech."},{"key":"10.1016\/j.micpath.2018.05.035_bib42","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1166\/jbns.2011.1042","article-title":"Encapsulation of antigenic secretory proteins of Mycobacterium tuberculosis in biopolymeric nanoparticles for possible aerosol delivery system","volume":"5","author":"Verma","year":"2011","journal-title":"J. Bionanoscience"}],"container-title":["Microbial Pathogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401018305187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401018305187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T01:53:50Z","timestamp":1661306030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0882401018305187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":42,"alternative-id":["S0882401018305187"],"URL":"https:\/\/doi.org\/10.1016\/j.micpath.2018.05.035","relation":{},"ISSN":["0882-4010"],"issn-type":[{"value":"0882-4010","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are chitosan natural polymers suitable as adjuvant\/delivery system for anti-tuberculosis vaccines?","name":"articletitle","label":"Article Title"},{"value":"Microbial Pathogenesis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.micpath.2018.05.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}